Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03855917 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir

Study acronym: STRIVE-4
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Feb 2026 to Jul 31, 2029v8
  2. Primary and study completion dates: Feb 2024 to Feb 2026v7
  3. Primary completion date: Feb 2023 to Feb 2024v6
  4. Primary completion date: Feb 2022 to Feb 2023
    • Study completion date: Feb 2023 to Feb 2024
    v5
  5. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Study sites: 2 to 3
    • Primary completion date: Nov 2021 to Feb 2022
    • Study completion date: Nov 2022 to Feb 2023
    • Start date changed from estimate of Nov 2020 to Feb 11, 2020
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Sep 2019 to Nov 2020
    • Primary completion date: Sep 2021 to Nov 2021
    • Study completion date: Sep 2022 to Nov 2022
    v3
  2. Start date: Apr 2019 to Sep 2019
    • Primary completion date: Apr 2021 to Sep 2021
    • Study completion date: Apr 2022 to Sep 2022
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to evaluate the efficacy, safety and feasibility of four weeks of sofosbuvir plus glecaprevir-pibrentasvir, followed by immediate retreatment of virological relapse with glecepravir-pibrentasvir for 12 weeks, in treatment-naïve participants with chronic HCV infection and early liver disease (F0-F2).
Trial Details
NCT Number NCT03855917
Lead Sponsor Kirby Institute
Conditions
(from sponsor)		 Hepatitis C
Related terms Hepatitis C
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov